AVTR vs. BNTX: Avantor vs. BioNTech Stock Comparison
How do Avantor (AVTR) and BioNTech (BNTX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and BioNTech (BNTX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while BNTX is classified in Biotechnology.
Avantor (AVTR) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AVTR | BNTX |
|---|---|---|
| Name | Avantor, Inc. | BioNTech SE American Depositary Share |
| Country/Region | United States | Germany |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 10.48 billion USD | 21.70 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 17, 2019 | October 10, 2019 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| Total Return (1Y) | 36.41% | -14.78% |
| Total Return (3Y, Annualized) | -5.02% | -3.99% |
| Total Return (5Y, Annualized) | -16.62% | -17.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 47.44% |
| Beta (5Y) | 0.94 | 1.30 |
| Max Drawdown (5Y) | -82.42% | -78.10% |
| Avg. Volume (3M) | 8.56M | 1.21M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | -0.40 |
| Sortino Ratio (1Y) | 1.17 | -0.59 |
Profitability
ROE (TTM)
BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Avantor (AVTR) reports 5.91%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.14%
- Max
- 109.18%
- Q3
- 6.23%
- BNTX
- -8.14%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Avantor (AVTR) reports 5.08%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-60.87%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BNTX
- -60.87%
Operating Margin (TTM)
BioNTech (BNTX) at 30.28% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.28%
- Max
- 83.12%
- BNTX
- 30.28%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| ROE (TTM) | 5.91% | -8.14% |
| ROA (TTM) | 2.83% | -4.04% |
| Net Margin (TTM) | 5.08% | -60.87% |
| Operating Margin (TTM) | 8.19% | 30.28% |
| Gross Margin (TTM) | 31.59% | 76.73% |
Growth
Revenue Growth
BioNTech (BNTX) at 4.32% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.
Growth Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 4.32% |
| Revenue Growth (3Y CAGR) | -4.46% | -45.06% |
| EPS Growth (YoY) | -175.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.55
- Max
- 25.13
- Q3
- 12.13
- BNTX
- 8.55
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Avantor (AVTR) at 0.63 runs a more typical debt-to-equity mix.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- BNTX
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 8.55 |
| Debt / Equity (MRQ) | 0.63 | 0.02 |
| Net Debt / EBITDA | 3.40 | -- |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Avantor (AVTR) trades at 30.94 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BNTX
- --
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while BioNTech (BNTX) at 8.96 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.96
- Max
- 58.18
- Q3
- 25.77
- BNTX
- 8.96
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Avantor (AVTR) at 1.80 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.09
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BNTX
- 1.09
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | BNTX |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | -- |
| P/S Ratio (TTM) | 1.58 | 8.96 |
| P/B Ratio (MRQ) | 1.80 | 1.09 |
| Free Cash Flow Yield (TTM) | 4.21% | -7.34% |